8-KOther EventsExhibits & Filings

BIOGEN INC. 8-K Report, Corporate Update (Feb 22, 2005)

Filed February 22, 2005For Securities:BIIB

Summary

Biogen Idec Inc. filed an 8-K on February 22, 2005, to report on positive developments regarding its multiple sclerosis drug, TYSABRI® (natalizumab). The company announced that the Phase 3 AFFIRM monotherapy study met its two-year primary endpoint, demonstrating that TYSABRI effectively slowed the progression of disability in patients with relapsing forms of multiple sclerosis. Furthermore, the drug sustained its efficacy in reducing clinical relapses over the two-year study period, consistent with previously reported one-year findings.

Key Highlights

  • 1Biogen Idec announced positive Phase 3 results for TYSABRI® (natalizumab) in relapsing multiple sclerosis.
  • 2The AFFIRM monotherapy study met its two-year primary endpoint by demonstrating a slowing of disability progression.
  • 3TYSABRI sustained its efficacy in reducing clinical relapses over the two-year study period.
  • 4Results are consistent with previously reported one-year data, reinforcing the drug's efficacy.
  • 5This filing incorporates by reference a press release dated February 17, 2005, detailing these findings.

Frequently Asked Questions

The most important information for investors is the positive outcome of the TYSABRI Phase 3 AFFIRM study. The drug successfully met its primary endpoint by demonstrating the slowing of disability progression in multiple sclerosis patients over two years, and maintained its efficacy in reducing relapses, which is a significant positive development for the drug's potential.

TYSABRI® (natalizumab) is a drug developed by Biogen Idec. This filing specifically reports on its testing in patients with relapsing forms of multiple sclerosis.

This means that the clinical trial met its pre-defined main objective for the two-year mark. Specifically, patients treated with TYSABRI showed a statistically significant slower rate of worsening of their disability compared to a control group over the two-year study period, indicating a therapeutic benefit.

These results represent a sustained efficacy over a longer period. The press release and this filing indicate that the two-year results are consistent with the one-year results, confirming the drug's ongoing effectiveness rather than presenting entirely new efficacy data.